Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wonder if Leo is aware?
This is the line that got my attention:
IPIX Innovation Pharmaceuticals Inc: Updated rumor IPIX accepts buyout offer from Pfizer after long/ protracted negotiations.
PJ007, Anyone able to translate that scrambled message that you know of?
Justfactsmam, I like your thinking
"He's 80, has been an honorable fed for what, 50 years or so":)
"seems like right wing obsessive insanity." Its the Russians!!! (now for 5 yrs :)
Fauchi, Insider? Collusion? Self serving?
Edited: From another IHUB board.
If anyone is interested please see the attached document. It is the non disclosure agreements between Moderna and Dr. Fauci’s group NIAD. This document was obtained by Axios from a whistle blower and has been sitting on it. Similar to the Hunter Biden laptop. See page 105. This page is a material transfer agreement between Dr Fauci group and Ralph Baric at UNC Chapel Hill. This took place on Dec 12, 2019. The corona virus vaccine jointly owned by dr Fauci (NAID)and Moderna was provided to this man to perform challenge studies. These studies are redacted. By whom????? And why????
https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html#document/p105/a568569
Wouldn't it be a great day for the friday aftre market PR and open Mon up $5.00 :)
LEO'S REVENGE!
We have all heard of it, From Justfactsmam:
"More about Ridgeback...I posted months ago."..
Quote:
This is a potential huge Scam set up by a Dr. "turned Hedge fund Manager likely sanctioned by SEC (looking to verify he lost his lost h brokerage license) and his Wife, who is the owner (not him for obvious reasons) and has been around since early April.
"Hedge Funder Wayne Holman Buys Star Island Property for $28M
The latest buyer on Miami Beach's Star Island is a New York hedge funder linked to the SAC Advisors insider trading scandal."
Supposedly they were entering Phase 1 for safety and efficacy...big deal here is BARDA turned them down for funding. LIKELY SMELLED THE SCAM...and NO INDEPENDENT VERIFICATION of Studies?
Lots of vague associations going on here..and NOT GOOD ONES. Some ebola association...got some funding for EBOLA a while back...BUT NO FUNDING FOR COVID-19 Research!
At best this is another potential RNA study...none have shown statistical efficacy...
WHY no funding?... likely Husband and Wife linkage and...team with no experience in the field. She is owner of Ridgeback, with business degree and he, first a Family Practice with no specialty, becomes Hedge Fund manager, associated with (SAC) insider trading scandal ...She applies for and did not independently demonstrate efficacy thresholds..NO GRANT MONIES...AND...your con Husband only a "scientific consultant"?
Appear to be Simply a "con couple" trying to make a big buck on theory and funding from Barda again. Last time appears to have gone nowhere. This time BARDA NOT BITING.
start with their robust web site, deep into research (not): https://www.ridgebackbio.com/...$100 web site from Wix.
IPIX is applying for Grants AFTER INDEPENDENT VERIFICATION of Science by RBLs AND with RBL!
More importantly...even IF another company shows any incremental steps of potential therapeutic...that does not detract from IPIX/Brilacidin's clinical successes and real Phase 1 and Phase II Human Trials...
presentation of Ridgeback.. are you asking readers to infer that any other company's potential successes means Brilacidin is a failure or the other is far superior.
Brilacidin tests and successful outcomes do and will continue to stand on their own.
"The FDA has awarded Kevetrin Orphan Drug status for Ovarian Cancer, Pancreatic Cancer, and Retinoblastoma, qualifying it for developmental incentives and an extra 7 years of market exclusivity upon drug approval. The FDA also has granted Kevetrin Rare Pediatric Disease designation for childhood Retinoblastoma." http://www.ipharminc.com/kevetrin-1
WE tend to forget what CTIX was about: http://www.ipharminc.com/kevetrin-1
Innovation Pharmaceuticals Announces Publication of Independent Research on Kevetrin, the Company’s p53 Drug Candidate, in Oncology Reports
PRESS RELEASE GlobeNewswire
Sep. 8, 2020, 10:00 AM
BEVERLY, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce the publication of independent research, in Oncology Reports, a leading oncology journal, supporting the therapeutic potential of Kevetrin, the Company’s p53-modulating anti-cancer drug candidate, in treating Acute Myeloid Leukemia (AML). AML accounts for approximately one-quarter to one-third of all leukemias worldwide and has a 5-year survival rate of only 24 percent.
In the recently published Kevetrin AML research, linked below, Kevetrin treatment was shown to arrest cell growth and cause cell death (apoptosis) in AML cells. Multiple p53 targets, several cellular processes and oncogenic pathways were also shown to be positively impacted by Kevetrin. Kevetrin was further shown to exhibit preferential cytotoxic activity against leukemia blast cells, while largely not affecting the immune microenvironment, supporting a less toxic drug profile.
The researchers concluded: “These findings suggest that Kevetrin may be a promising therapeutic option for patients with both wild-type and TP53-mutant AML.”
“These compelling research findings, by independent researchers, confirm Kevetrin’s treatment potential in AML—a serious blood cancer in great need of novel treatments,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “A Phase 2a clinical trial of Kevetrin in late-stage platinum-resistant ovarian cancer revealed intra-tumor p53 modulation. The Company is planning to formulate Kevetrin for oral delivery, leveraging drug pharmacokinetics and enhancing ease of use. These new published findings provide valuable insights into Kevetrin’s anti-cancer properties.”
As a gene-based therapy, should Kevetrin demonstrate efficacy in clinical testing, its regulatory pathway to approval might be expedited. The Food and Drug Administration (FDA) hassignaled strong support for development of gene therapies. Two gene therapies for cancers of the blood (Kymriah and Yescarta) were approved for genetically-driven diseases based primarily on results from mid-stage, single-arm, open-label clinical trials. FDA’s efficacy determination for Kymriah was based on 92 evaluable patients, and 108 evaluable patients for Yescarta.
The Company will keep shareholders apprised of developments in our Kevetrin program. In separate news, the Company will be submitting a briefing package shortly to the FDA in preparation for our planned clinical study of Brilacidin for COVID-19.
Napolitano R, et al. “Kevetrin Induces Apoptosis in TP53 Wild-Type and Mutant Acute Myeloid Leukemia Cells.” Oncol Rep. 2020 Oct; 44(4): 1561–1573.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448420/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448420/pdf/or-44-04-1561.pdf (pdf)
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Kevetrin and p53
Kevetrin is a small molecule that has demonstrated the potential of becoming a breakthrough cancer treatment by modulating p53, a protein frequently referred to as the “Guardian of the Genome” due to its critical role in controlling cell mutations. In a majority of cancers, the p53 pathway is mutated, preventing the body from performing its natural anti-tumor functions. Kevetrin, by intravenous dosing, has successfully completed a Phase 1 clinical trial in advanced solid tumors and a Phase 2a clinical trial in late-stage ovarian cancer. The company plans on completing oral toxicology studies and changing the dosing to an oral formulation (tablet or capsule), subject to available financial resources. The Food and Drug Administration (FDA) has awarded Orphan Drug status for Kevetrin in ovarian cancer, pancreatic cancer, and retinoblastoma, qualifying it for developmental incentives and market exclusivities upon any future regulatory approval. The FDA also has granted Kevetrin Rare Pediatric Disease designation for childhood retinoblastoma.
Learn more here:
http://www.ipharminc.com/kevetrin-1/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection. Brilacidin, based on promising in vitro antiviral activity against SARS-CoV-2, is being evaluated as a potential treatment for COVID-19. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations and has successfully completed a Phase 2 trial in Ovarian Cancer. More information is available on the Company website at www.ipharminc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning our future drug development plans, statements regarding the antiviral capabilities and therapeutic potential of Brilacidin and its impact on SARS-CoV-2 (COVID-19) and other coronaviruses, other statements regarding future product developments and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks but not limited to risks related to conducting pre-clinical studies and seeking IND regulatory approval for Brilacidin and Kevetrin clinical trials; that prior test results may not be replicated in future studies and trials, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Company’s licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments, or the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.com
https://markets.businessinsider.com/news/stocks/innovation-pharmaceuticals-announces-publication-of-independent-research-on-kevetrin-the-company-s-p53-drug-candidate-in-oncology-reports-1029570050
SAVE AMERICA PAC
https://www.donaldjtrump.com/news/archives/2021/02
President Donald Trump walks off stage after an address to the Conservative Political Action Conference (CPAC) held in the Hyatt Regency in Orlando, Florida, on Feb. 28, 2021. (Joe Raedle/Getty Images)
President Donald Trump walks off stage after an address to the Conservative Political Action Conference (CPAC) held in the Hyatt Regency in Orlando, Florida, on Feb. 28, 2021. (Joe Raedle/Getty Images)
DONALD TRUMP
Trump Builds Leverage for ‘Overhaul’ of GOP With Fundraising Gambit
BY IVAN PENTCHOUKOV March 9, 2021 Updated: March 9, 2021
Former President Donald Trump over the past two weeks laid the foundation for exerting financial leverage over the Republican Party apparatus by instructing supporters to donate solely to his campaign website and political action committee, while demanding that the Republican National Committee (RNC) and its congressional chamber affiliates stop using his name and likeness to raise funds.
The stratagem is all but sure to split a substantial chunk of donations from the GOP and allow Trump to divert money from the RNC that could otherwise end up bankrolling the campaigns of the Republicans he is looking to oust. Given the president’s immense popularity among Republican voters, the RNC, the National Republican Senatorial Committee (NRSC), and the National Republican Congressional Committee (NRCC) face the dire prospect of raising funds with the handicap of being unable to use the name of the man who reigns supreme over the Republican Party due to his ability to energize the base and pull in a mass of small donors.
“He could cripple them doing this. They will have to rely on larger donors that cannot give unlimited sums of money,” Rich Baris, the director of Big Data Poll, told The Epoch Times.
“And that low-dollar base that drove Trump’s fundraising when he had a committee joint with the RNC … it’ll probably take some time, but most of them will get the message, and they’ll give to Trump’s PAC instead.”
The RNC on March 8 brushed aside Trump’s cease-and-desist letter, arguing in a letter obtained by The Epoch Times that it’s within the organization’s First Amendment rights to use the name of a public figure to raise funds.
The move prompted a fiery statement from Trump again instructing supporters to donate to his website and political action committee (PAC) rather than the RNC.
“No more money for RINOS,” Trump said in a statement, using an acronym for Republicans in Name Only. “They do nothing but hurt the Republican Party and our great voting base—they will never lead us to Greatness. Send your donation to Save America PAC at DonaldJTrump.com. We will bring it all back stronger than ever before!”
The RNC’s letter, written by chief counsel Justin Riemer, states that Trump and RNC Chairwoman Ronna McDaniel enjoy a close relationship, alleging that the former president over the weekend reaffirmed to her that he approves of the RNC’s current use of his name in fundraising and other materials, including for an upcoming donor retreat event in Palm Beach, Florida, in which Trump is slated to participate.
“The RNC has not sent any fundraising requests in President Trump’s name or used his image since before he left office, nor would it do so without his prior approval,” Riemer wrote.
Trump had made the initial appeal to supporters to donate only to his PAC, during a highly anticipated speech at the Conservative Political Action Conference (CPAC) on Feb. 28. The address marked Trump’s first public appearance after leaving the White House. The excommunication of his social media profiles by the Silicon Valley giants amplified the silence and suspense ahead of the speech.
As a testament to Trump’s appeal, the speech was viewed by 5.7 million people on Fox News, breaking the network’s all-time Sunday viewership record. More than 30 million people have watched the speech online, according to streaming data from VFT Solutions.
Trump made the fundraising remarks during the portion of the CPAC speech devoted to election integrity. He expressed doubts over the legitimacy of President Joe Biden’s 2020 victory. The choice of context is notable because the RNC appears to have left Trump to vie for himself in the aftermath of the Nov. 3 election. Neither the RNC nor the NRSC nor the NRCC was a party to any of the election lawsuits Trump filed. McDaniel, the RNC chairwoman, has not gone on record to affirm Trump’s doubts about the election.
Michael Johns, co-founder of the National Tea Party movement, told The Epoch Times: “You look at the election integrity issues of 2020 and ask who is responsible for maintaining that integrity, and it would have to fall back on the RNC, which raised about $900 million this last election cycle and appears not to have been sufficiently involved, before the election, during the election, or after the election in contesting it.”
“It’s incredible to me that we’ve had to rely on an American entrepreneur who owns a pillow company and on a very bright trade adviser … to take up the arguments that you would think, logically, would be made by the RNC,” Johns added, referring to MyPillow CEO Mike Lindell and Peter Navarro, Trump’s director of the White House Office of Trade and Manufacturing Policy.
A week after the CPAC speech, a Trump adviser confirmed to The Epoch Times that the president sent cease-and-desist letters demanding that the RNC, the NRSC, and the NRCC stop using his name and likeness. Calls placed to the three committees went unanswered.
As of the morning of March 7, the NRCC was still using Trump’s name in its standard messaging for new email list registrations. The home page of the NRSC advertised Trump T-shirts from its online shop.
Setting up a war chest of his own will allow Trump to spend money against Republican incumbents who would otherwise receive the backing of the RNC. That includes Sen. Lisa Murkowski (R-Alaska), who is the only Republican senator running for reelection in 2022 of the seven who voted to convict Trump during the second impeachment trial, which concluded with the Senate acquitting Trump. The former president issued a statement on March 6 vowing to campaign against Murkowski, who is serving her third term.
There is no precedent in modern politics of the RNC backing a primary challenger against a Republican incumbent, according to Johns, the National Tea Party movement co-founder. Johns said the RNC hasn’t been meaningfully aligned with Trump’s Make America Great Agenda (MAGA) and, over the past four years, has often backed primary opponents against pro-MAGA candidates. As a result, the 10 House Republicans who voted to impeach Trump would have been running for reelection with money the RNC raised using the president’s name.
“He ran to overhaul and save the country, but also to overhaul and save the Republican Party that was not addressing some of the core issues of the time, like China, trade, immigration, in a forceful enough way, and was relying on professional consultants, had become very insular, was not engaged in building the party out in much of a populist way,” Johns said.
“Four years later, that largely continues to be the case. The party operations, the party leadership are not completely Trump-driven. And it only makes sense that if the donor intent is to support President Trump’s 2024 candidacy, potentially, or whether it’s to support candidates that are Trump-aligned in 2022, that you would donate through his vehicles directly and not to the party, which is going to continue to back, for instance, these 10 House members who voted for his impeachment,” he said. “The president’s initiatives are sensible, and perhaps even overdue.”
Aside from Murkowski, five establishment GOP senators will not run for reelection in 2022, including two who voted to convict Trump during the Senate trial, Sen. Patrick J. Toomey (R-Pa.) and Sen. Richard Burr (R-N.C.). The retirements, coupled with Trump’s fundraising stratagem, open the field for Trump to fundamentally reshape the Senate by backing candidates aligned with his America First platform.
Trump will also be able to invest in the primary challenge against Rep. Liz Cheney (R-Wyo.), who issued a scathing statement against him before voting in favor of impeaching him.
Jason Meister, a member of the Trump advisory board, told The Epoch Times: “This keeps him in control. They need to work through him if they want to raise money off of him. I don’t see why anyone would think they could continue to ride his coattails without his approval. Not to mention that many candidates that these organizations support aren’t America First candidates.
“Trump needs his supporters flush with cash so that when it’s time to raise money for America First candidates and the America First agenda, they have the resources. There’s only so many times you can go to the same well.”
In another sign of Trump’s expanding ascendancy over the Republican Party, the RNC has moved a portion of its spring donor retreat to Mar-a-Lago, according to a Republican attending the event. Mar-a-Lago is Trump’s exclusive club and residence in Palm Beach, Florida.
Zachary Stieber contributed to this report.
Follow Ivan on Twitter: @ivanpentchoukov
New NASA satellite data prove carbon dioxide is GREENING the Earth and restoring forests
MAR 5, 2121
The latest Vegetation Index data from NASA shows that the Earth is getting progressively “greener” and lusher over time.
The planet is 10 percent greener today than it was in 2000, NASA says, which means better conditions for growing crops. Forests are also expanding while deserts are becoming more fertile and usable for agriculture.
All in all, the global Vegetation Index rose from 0.0936 to 0.1029 between 2000 and 2021, a 9.94 percent increase.
“10 percent greening in 20 years! We are incredibly fortunate!” announced Zoe Phin, a researcher who compiled the data into a chart for her blog.
“I just wish everyone felt that way. But you know not everyone does. To the extent that humans enhance global greening is precisely what social parasites want to tax and regulate. No good deed goes unpunished.”
A separate German study found that the globe has been greening for at least the past three decades.
Satellite imagery suggests that vegetation has been expanding at a growing rate, contracting the gloom-and-doom narrative being spread by the climate alarmists.
Back in 2018, research found that the Sahara Desert, the largest in the world, had shrunk by more than 8 percent over the past three decades. This is truly profound as the Sahara covers an expansive 9.2 million square kilometers of territory.
“Eight percent means more than 700,000 square kilometers more area that’s become green – an area almost as big as Germany and France combined,” reports P. Gosselin.
“So in terms of vegetation, the planet probably hasn’t had it this nice in about 1,000 years.”
“Global warming” is a good thing – it’s healing the planet!
Most of this greening is caused by greenhouse gases – you know, those “horrible” emissions that the climate fanatics insist are going to kill us all.
Truth be told, greenhouse gases are making the planet more habitable for humans and other life forms.
One study calls this phenomenon carbon dioxide (CO2) fertilization, which is far more accurate than calling it CO2 “pollution” as many in the mainstream media continue to do.
By the year 2100, all this greening will offset 17 years’ worth of anthropogenic CO2 emissions, rendering all this “pollution” as if it never even happened. In other words, there will be only benefits and no drawbacks from all this “global warming” that is taking place.
“There are many more studies underpinning the good news of the greening planet – thanks in large part to mankind,” notes Gosselin. “It’s not as bad as the crybaby activists and media depict it to be. Not even close.”
The problem is that there is no money to be made from telling everyone that the planet is just fine, and to continue living as normal. There would be no “need” for a “green” shift away from fossil fuels, and no “need” to stop eating meat, among other such nonsense.
The powers that be have to keep the “climate change” ruse going in order to advance their globalist agenda. Without climate change, there would be no excuse to steal people’s freedoms and liberties while imposing hell on earth as the “solution” to all of these manufactured climate woes.
“Food security will always be a factor because as long as global population increases, so must global agricultural production increase. That said (the need for agricultural output to keep pace with population), by far the biggest threat to humanity, is NOT climate change,” wrote one commenter at WattsUpWithThat.com.
“The biggest threat to humanity and resulting environmental destruction that a global famine would bring is Climate Change policy – the UN’s Socialist-Marxist climate policy to destroy access to affordable, abundant fossil fuels necessary to sustain global agricultural output.”
https://www.dcclothesline.com/2021/03/05/new-nasa-satellite-data-prove-carbon-dioxide-is-greening-the-earth-and-restoring-forests/
All we need is a nudge and we will rocket.
Bid
0.3101
Ask
0.3199
I find the delayed price quotes here to be a depressent to share price.
Wouldn't that be a hoot, Russians becoming billionaires buying an OTC IPIX :)
ymbol
IPIX
LastQuoteHelp
0.318
Change
+0.033 (+11.58%)
Bid
0.305
Ask
0.314
High
0.319
Low
0.285
Volume
591,479
Time (ET)
10:02:39 AM
Refresh
Trade
Interpretative Summary for March 5, 2021
An Effective New Tool in the Toolbox
Vaccines are critical tools for ending the COVID-19 pandemic, and we just got a new one. On February 28, CDC released an official recommendation to use Johnson & Johnson’s Janssen (J&J/Janssen) vaccine, which is safe and effective in preventing severe COVID-19 illness, hospitalization, and death. This vaccine is being distributed now. The J&J/Janssen vaccine protects against COVID-19 in one dose, not two, and can be stored at a standard refrigerator temperature instead of needing colder storage. These advantages can help the vaccine reach most communities and mobile sites, as the supply of vaccines increases.
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html
Thanks JFM for the reminder great update.
Austria Suspends Use of AstraZeneca COVID-19 Vaccine Batch After Death
BY REUTERS March 7, 2021 Updated: March 7, 2021 biggersmaller Print
ZURICH—Austrian authorities have suspended inoculations with a batch of AstraZeneca’s COVID-19 vaccine as a precaution while investigating the death of one person and the illness of another after the shots, a health agency said on March 7.
https://www.theepochtimes.com/austria-suspends-astrazeneca-covid-19-vaccine-batch-after-death_3723690.html?utm_source=news&utm_medium=email&utm_campaign=breaking-2021-03-07-2
“The Federal Office for Safety in Health Care (BASG) has received two reports in a temporal connection with a vaccination from the same batch of the AstraZeneca vaccine in the district clinic of Zwettl” in Lower Austria province, it said.
One 49-year-old woman died as a result of severe coagulation disorders, while a 35-year-old woman developed a pulmonary embolism and is recovering, it said. A pulmonary embolism is an acute lung disease caused by a dislodged blood clot.
“Currently, there is no evidence of a causal relationship with the vaccination,” BASG said.
Austrian newspaper Niederoesterreichische Nachrichten as well as broadcaster ORF and the APA news agency reported that the women were both nurses who worked at the Zwettl clinic.
BASG said blood clotting wasn’t among the known side effects of the vaccine; it is pursuing its investigation vigorously to completely rule out any possible link.
“As a precautionary measure, the remaining stocks of the affected vaccine batch are no longer being issued or vaccinated,” it added.
An AstraZeneca spokesman said: “There have been no confirmed serious adverse events associated with the vaccine,” adding that all batches are subject to strict and rigorous quality controls.
Trials and real-world experience so far suggests the vaccine is safe and effective and it had been approved for use in well over 50 countries, he said.
AstraZeneca also said it was in contact with Austrian authorities and would fully support the investigation.
European Union regulators at the end of January approved the product, saying it was effective and safe to use, while the World Health Organization (WHO) in mid-February listed the product for emergency use.
Adverse reactions seen in trials were short-lived for the most part and blood clotting issues weren’t reported.
A safety assessment by Germany’s vaccine regulator of more than 360,000 people who received the Astra vaccine in the country between the launch in early February and Feb. 26 concluded that adverse reactions were in line with the safety profile described in clinical trials.
By Michael Shields and Ludwig Burger
Austria Suspends Use of AstraZeneca COVID-19 Vaccine Batch After Death
BY REUTERS March 7, 2021 Updated: March 7, 2021 biggersmaller Print
ZURICH—Austrian authorities have suspended inoculations with a batch of AstraZeneca’s COVID-19 vaccine as a precaution while investigating the death of one person and the illness of another after the shots, a health agency said on March 7.
https://www.theepochtimes.com/austria-suspends-astrazeneca-covid-19-vaccine-batch-after-death_3723690.html?utm_source=news&utm_medium=email&utm_campaign=breaking-2021-03-07-2
“The Federal Office for Safety in Health Care (BASG) has received two reports in a temporal connection with a vaccination from the same batch of the AstraZeneca vaccine in the district clinic of Zwettl” in Lower Austria province, it said.
One 49-year-old woman died as a result of severe coagulation disorders, while a 35-year-old woman developed a pulmonary embolism and is recovering, it said. A pulmonary embolism is an acute lung disease caused by a dislodged blood clot.
“Currently, there is no evidence of a causal relationship with the vaccination,” BASG said.
Austrian newspaper Niederoesterreichische Nachrichten as well as broadcaster ORF and the APA news agency reported that the women were both nurses who worked at the Zwettl clinic.
BASG said blood clotting wasn’t among the known side effects of the vaccine; it is pursuing its investigation vigorously to completely rule out any possible link.
“As a precautionary measure, the remaining stocks of the affected vaccine batch are no longer being issued or vaccinated,” it added.
An AstraZeneca spokesman said: “There have been no confirmed serious adverse events associated with the vaccine,” adding that all batches are subject to strict and rigorous quality controls.
Trials and real-world experience so far suggests the vaccine is safe and effective and it had been approved for use in well over 50 countries, he said.
AstraZeneca also said it was in contact with Austrian authorities and would fully support the investigation.
European Union regulators at the end of January approved the product, saying it was effective and safe to use, while the World Health Organization (WHO) in mid-February listed the product for emergency use.
Adverse reactions seen in trials were short-lived for the most part and blood clotting issues weren’t reported.
A safety assessment by Germany’s vaccine regulator of more than 360,000 people who received the Astra vaccine in the country between the launch in early February and Feb. 26 concluded that adverse reactions were in line with the safety profile described in clinical trials.
By Michael Shields and Ludwig Burger
Adverse Incident Reports Show 966 Deaths Following Vaccination for COVID-19
https://www.theepochtimes.com/adverse-incident-reports-show-966-deaths-following-vaccination-for-covid-19_3723384.html?utm_source=morningbrief&utm_medium=email&utm_campaign=mb-2021-03-07
According to adverse incident reports collected by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) 966 individuals have died after having received an mRNA vaccine for COVID-19.
Between Dec. 14 and Feb. 19, 19,769 reports were made to the Vaccine Adverse Events Reporting System (VAERS) following immunizations with either the Moderna or Pfizer BioNTech mRNA vaccines (the only two vaccines given during the time period assessed). At this time, VAERS data is not available after Feb. 19.
The 966 deaths represent 5 percent of the total number of adverse events reports. Of those who died, 86, (8.9 percent) died on the same day they got the shot. An additional 129, (13.4 percent) died within one day. An additional 97 died within 2 days, and 61 within 3 days.
A total of 514 (53.2 percent) died within a week. 173 died within 7-13 days. 106 within 14-20 days.
85 percent of deaths occurred in individuals over 60; below 60 there were five deaths among those aged 20-29; 8 aged 30-39; 20 aged 40-49; and 57 aged 50-59.
For detailed information drawn from the VAERS reports, see charts provided at the link at the end of this article.
Epoch Times Photo
Information drawn from VAERS reports on mRNA vaccinations for COVID-19. (source: CDC)
Comparison With Influenza Vaccines
Neither of the mRNA vaccines are FDA approved, rather, they have Emergency Use Approval (EUA). They represent a departure from traditional vaccines in that they do not use any part of the suspected pathogen to stimulate the immune system, but rather, nucleoside messenger RNA.
Dr. Christian Perrone, head of Infectious Disease at Hopital de Garches in France, stated in a complaint filed in Europe:
“The first vaccines they are offering us are not vaccines. They are gene therapy products. They…inject nucleic acids that will cause our own cells to produce elements of the virus.”
The death rate following COVID mRNA vaccination is much higher than that following influenza vaccination.
The CDC’s data allows only a ballpark estimation of the rate of deaths following flu vaccination.
In the 2019-2020 influenza season the CDC reports that 51.8 percent of the U.S. population received a vaccine, which is approximately 170 million people.
VAERS reports that in the calendar year 2019 (not the 2019-2020 influenza season) there were 45 deaths following vaccination. To provide context, in 2018 VAERS reports 46 deaths, and in 2017 it reports 20 deaths.
The 45 deaths in 2019 are occurring at a rate of 0.0000265 percent, when calculated using the number of vaccines given in the 2019-2020 influenza season.
As of Feb. 19, 41,977,401 COVID vaccinations had been given with 966 deaths reported following vaccination, which is approximately a rate of .0023 percent.
The VAERS System
VAERS was put in place in 1990, to capture unforeseen reactions from vaccines.
VAERS is criticized both for the fact that anybody can submit a report, and for the fact that it catches only a fraction of the adverse incidents.
The VAERS website describes the system in this way:
“Established in 1990, the Vaccine Adverse Event Reporting System (VAERS) is a national early warning system to detect possible safety problems in U.S.-licensed vaccines. VAERS is co-managed by the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA). VAERS accepts and analyzes reports of adverse events (possible side effects) after a person has received a vaccination. Anyone can report an adverse event to VAERS. Healthcare professionals are required to report certain adverse events and vaccine manufacturers are required to report all adverse events that come to their attention.
“VAERS is a passive reporting system, meaning it relies on individuals to send in reports of their experiences to CDC and FDA. VAERS is not designed to determine if a vaccine caused a health problem, but is especially useful for detecting unusual or unexpected patterns of adverse event reporting that might indicate a possible safety problem with a vaccine. This way, VAERS can provide CDC and FDA with valuable information that additional work and evaluation is necessary to further assess a possible safety concern.”
Without a medical diagnosis or autopsy, the report of an adverse incident following a vaccination is not proof that the vaccination caused any particular symptoms.
In a reply to The Epoch Times, about the VAERS death report, Steven Danehy, Director of Global Media Relations for Pfizer, wrote:
“To date, millions of people have been vaccinated with our vaccine. Serious adverse events, including deaths that are unrelated to the vaccine, are unfortunately likely to occur at a similar rate as they would in the general population.”
Moderna has not responded to requests for comment.
The VAERS database is dense with information and can be difficult for some users to follow. The Epoch Times has extracted its data as clearly as possible in charts provided in the link below.
At the link below are charts containing: on the tab “All Deaths Readable” descriptions of what happened to the patients—effects they experienced as reported by health care workers and/or relatives, or other witnesses; VAERS ID numbers (used to look up a complete file on the VAERS database); vaccination type; manufacturer; vaccination name; date received; age, gender and state of each recipient; as well as medical history; and other medications patients were taking.
Summary_of_VAERS_deaths_through_Feb_19th
Their going to have plenty of money to buy candy with soon, they are taking 1.9 trillion from our great.great.great grandkids. Its all been spent to that point.
Adverse Incident Reports Show 966 Deaths Following Vaccination for COVID-19
https://www.theepochtimes.com/adverse-incident-reports-show-966-deaths-following-vaccination-for-covid-19_3723384.html?utm_source=morningbrief&utm_medium=email&utm_campaign=mb-2021-03-07
According to adverse incident reports collected by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) 966 individuals have died after having received an mRNA vaccine for COVID-19.
Between Dec. 14 and Feb. 19, 19,769 reports were made to the Vaccine Adverse Events Reporting System (VAERS) following immunizations with either the Moderna or Pfizer BioNTech mRNA vaccines (the only two vaccines given during the time period assessed). At this time, VAERS data is not available after Feb. 19.
The 966 deaths represent 5 percent of the total number of adverse events reports. Of those who died, 86, (8.9 percent) died on the same day they got the shot. An additional 129, (13.4 percent) died within one day. An additional 97 died within 2 days, and 61 within 3 days.
A total of 514 (53.2 percent) died within a week. 173 died within 7-13 days. 106 within 14-20 days.
85 percent of deaths occurred in individuals over 60; below 60 there were five deaths among those aged 20-29; 8 aged 30-39; 20 aged 40-49; and 57 aged 50-59.
For detailed information drawn from the VAERS reports, see charts provided at the link at the end of this article.
Epoch Times Photo
Information drawn from VAERS reports on mRNA vaccinations for COVID-19. (source: CDC)
Comparison With Influenza Vaccines
Neither of the mRNA vaccines are FDA approved, rather, they have Emergency Use Approval (EUA). They represent a departure from traditional vaccines in that they do not use any part of the suspected pathogen to stimulate the immune system, but rather, nucleoside messenger RNA.
Dr. Christian Perrone, head of Infectious Disease at Hopital de Garches in France, stated in a complaint filed in Europe:
“The first vaccines they are offering us are not vaccines. They are gene therapy products. They…inject nucleic acids that will cause our own cells to produce elements of the virus.”
The death rate following COVID mRNA vaccination is much higher than that following influenza vaccination.
The CDC’s data allows only a ballpark estimation of the rate of deaths following flu vaccination.
In the 2019-2020 influenza season the CDC reports that 51.8 percent of the U.S. population received a vaccine, which is approximately 170 million people.
VAERS reports that in the calendar year 2019 (not the 2019-2020 influenza season) there were 45 deaths following vaccination. To provide context, in 2018 VAERS reports 46 deaths, and in 2017 it reports 20 deaths.
The 45 deaths in 2019 are occurring at a rate of 0.0000265 percent, when calculated using the number of vaccines given in the 2019-2020 influenza season.
As of Feb. 19, 41,977,401 COVID vaccinations had been given with 966 deaths reported following vaccination, which is approximately a rate of .0023 percent.
The VAERS System
VAERS was put in place in 1990, to capture unforeseen reactions from vaccines.
VAERS is criticized both for the fact that anybody can submit a report, and for the fact that it catches only a fraction of the adverse incidents.
The VAERS website describes the system in this way:
“Established in 1990, the Vaccine Adverse Event Reporting System (VAERS) is a national early warning system to detect possible safety problems in U.S.-licensed vaccines. VAERS is co-managed by the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA). VAERS accepts and analyzes reports of adverse events (possible side effects) after a person has received a vaccination. Anyone can report an adverse event to VAERS. Healthcare professionals are required to report certain adverse events and vaccine manufacturers are required to report all adverse events that come to their attention.
“VAERS is a passive reporting system, meaning it relies on individuals to send in reports of their experiences to CDC and FDA. VAERS is not designed to determine if a vaccine caused a health problem, but is especially useful for detecting unusual or unexpected patterns of adverse event reporting that might indicate a possible safety problem with a vaccine. This way, VAERS can provide CDC and FDA with valuable information that additional work and evaluation is necessary to further assess a possible safety concern.”
Without a medical diagnosis or autopsy, the report of an adverse incident following a vaccination is not proof that the vaccination caused any particular symptoms.
In a reply to The Epoch Times, about the VAERS death report, Steven Danehy, Director of Global Media Relations for Pfizer, wrote:
“To date, millions of people have been vaccinated with our vaccine. Serious adverse events, including deaths that are unrelated to the vaccine, are unfortunately likely to occur at a similar rate as they would in the general population.”
Moderna has not responded to requests for comment.
The VAERS database is dense with information and can be difficult for some users to follow. The Epoch Times has extracted its data as clearly as possible in charts provided in the link below.
At the link below are charts containing: on the tab “All Deaths Readable” descriptions of what happened to the patients—effects they experienced as reported by health care workers and/or relatives, or other witnesses; VAERS ID numbers (used to look up a complete file on the VAERS database); vaccination type; manufacturer; vaccination name; date received; age, gender and state of each recipient; as well as medical history; and other medications patients were taking.
Summary_of_VAERS_deaths_through_Feb_19th
I want to thank every one for the terrific response and exposure of the back ground on the story on Molnupiravir very impressive that there are so many here wish to participate. THANK YOU ALL!
Molnupiravir: Last of the Small-Molecule Coronavirus Hopes? Did we just drop out? Need some analysis?
https://blogs.sciencemag.org/pipeline/archives/2021/03/04/molnupiravir-last-of-the-small-molecule-coronavirus-hopes
dp70 out resident Astrologist. Just want to remind our Astrologist students and practitioners:
News days, 1 day + or- ignore weekends:
March 8 through March 10 – this could be very public news that trial has actually ended with improvement in patients. If so, then this could increase sp (unable to speculate how much) and the company having access to more money for a third trial.
March 13 – the company could be compiling the data from the trial results and with Mercury (rules data and information) in positive aspect to Pluto (the trial). This data could possibly mean a PR about results.
March 21 – Jupiter aspecting charts Sun/Neptune positive aspect. This could be another indication of being granted EUA due to positive trial results.
BOO, I believe just the fact the trials are proceeding is very positive, maybe a PR here and there will suffice and drive share price. There could be an EUA in our future before the trial is finished that would be the ultimate interim.
There is no way to keep the information locked up, if a patient gets out of bed and walks out of the hospital after treatment then it is public. They may not know if one patient was treated but when others do the same its not magic, its Brilacidin.JMO
Trial begin on the 22nd, there are some results already known and the trial is proceeding. Very positive indicaes Brilacidin is working.
mr40, great catch, and post.
Another one bites the dust:
Brii Bio joins the NIH graveyard alongside GSK, Lilly after flopping antibody study in hospitalized Covid-19 patients
https://endpts.com/brii-bio-joins-the-nih-graveyard-alongside-gsk-lilly-after-flopping-antibody-study-in-hospitalized-covid-19-patients/?utm_medium=email&utm_campaign=Friday%20March%205%20AMBER%20PLEASE%20USE&utm_content=Friday%20March%205%20AMBER%20PLEASE%20USE+CID_d7a20d930b5bd487f6d1277e6c588374&utm_source=ENDPOINTS%20emails&utm_term=Brii%20Bio%20joins%20the%20NIH%20graveyard%20alongside%20GSK%20Lilly%20after%20flopping%20antibody%20study%20in%20hospitalized%20Covid-19%20patients
Current price has no relevance as to the fair market valure of Innovation Pharmaceuticals anyone who believes that .30 cents is the current value "doesn't know their A** from a hole in the ground">
Stock price does matter, it is the key to value and because we are so undervalued the current price doesn't reflect what our true market value is, it is "over" 600% undervalued we should be selling at between 6 and 12 dollars then add your premium. I've never seen a company with so much potential and so under valued. Hell, we could be priced right now at $20.00 based on our pipeline then add the premium.
5 dollars my ass!
THAT IS EXACTLY THE REASON LEO ISN'T GOING TO SELL!
MinnieM, Really wouldn't be interested in a sale but if it happened, so be it, as long as we get a fair price otherwise I would love to live long enough to see everything they are going after mature.
Thanks, dp70.
Yeah, we don't get pummeled, we have been driven down with a pile driver, for years now.
TD, Why would a BP care whether its a NASDAQ company or a private company if we have the goods?
Just saw this this AM, for 1 Phase 3 ready drug: Phase III ready, https://endpts.com/amgen-snaps-up-cancer-drug-player-five-prime-adding-phiii-ready-fgfr2b-drug-in-2b-ma-play/
Endpoints News (https://endpts.com/amgen-snaps-up-cancer-drug-player-five-prime-adding-phiii-ready-fgfr2b-drug-in-2b-ma-play/?utm_source=dlvr.it&utm_medium=twitter)
Amgen snaps up cancer drug player Five Prime, adding PhIII-ready FGFR2b drug in $2B M&A play
Amgen is making a long-awaited move on the M&A side, buying South San Francisco-based Five Prime $FPRX for close to $2 billion
WE currently have 2 Phase 3 ready drugs and possibly a 3rd plus a phase 2 Cancer drug ready and some consider us less vauable than them?
http://www.ipharminc.com/stages-of-development
Dominion counting:)
That is a beauty, WOW!